A rapid blood-based diagnostic modality to detect pancreatic ductal adenocarcinoma (PDAC) with high accuracy is an unmet medical need. The study aimed to validate a unique diagnosis system using Probe Electrospray Ionization Mass Spectrometry (PESI-MS) and Machine Learning to the diagnosis of PDAC. Peripheral blood samples were collected from a total of 322 consecutive PDAC patients and 265 controls with a family history of PDAC. Five µl of serum samples were analyzed using PESI-MS system. The mass spectra from each specimen were then fed into machine learning algorithms to discriminate between control and cancer cases. A total of 587 serum samples were analyzed. The sensitivity of the machine learning algorithm using PESI-MS profiles to id...
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer characterized by multiple molecular alter...
Pancreatic ductal adenocarcinoma (PDAC) is an intractable cancer and a leading cause of cancer death...
Purpose: Each year in the United States, � 30,000 people die from pancreatic cancer. Fewer than 5 %...
A rapid blood-based diagnostic modality to detect pancreatic ductal adenocarcinoma (PDAC) with high ...
PURPOSE: We determined whether a large, multianalyte panel of circulating biomarkers can improve det...
International audienceBackground Pancreatic cancer (PC) represents a substantial public health burde...
Despite numerous diagnostic and therapeutic advances, pancreatic ductal adenocarcinoma (PDAC) has a ...
Pancreatic cancer is one of the most fatal types of cancer due to its difficulty of being diagnosed ...
BackgroundPancreatic cancer (PC) represents a substantial public health burden. Pancreatic cancer pa...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a limited number of effecti...
Due to its high mortality rate and asymptomatic nature, early detection rates of pancreatic ductal a...
Pancreatic ductal adenocarcinoma (PDAC) mortality rates are projected to rise by 2030 due to factors...
Comprehensive molecular landscaping studies reveal a potentially brighter future for pancreatic duct...
Purpose: The analysis of tumor-educated platelets (TEPs) is gaining momentum for the detection of di...
Pancreatic ductal adenocarcinoma (PDAC) is a disease where detection preceding clinical symptoms sig...
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer characterized by multiple molecular alter...
Pancreatic ductal adenocarcinoma (PDAC) is an intractable cancer and a leading cause of cancer death...
Purpose: Each year in the United States, � 30,000 people die from pancreatic cancer. Fewer than 5 %...
A rapid blood-based diagnostic modality to detect pancreatic ductal adenocarcinoma (PDAC) with high ...
PURPOSE: We determined whether a large, multianalyte panel of circulating biomarkers can improve det...
International audienceBackground Pancreatic cancer (PC) represents a substantial public health burde...
Despite numerous diagnostic and therapeutic advances, pancreatic ductal adenocarcinoma (PDAC) has a ...
Pancreatic cancer is one of the most fatal types of cancer due to its difficulty of being diagnosed ...
BackgroundPancreatic cancer (PC) represents a substantial public health burden. Pancreatic cancer pa...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a limited number of effecti...
Due to its high mortality rate and asymptomatic nature, early detection rates of pancreatic ductal a...
Pancreatic ductal adenocarcinoma (PDAC) mortality rates are projected to rise by 2030 due to factors...
Comprehensive molecular landscaping studies reveal a potentially brighter future for pancreatic duct...
Purpose: The analysis of tumor-educated platelets (TEPs) is gaining momentum for the detection of di...
Pancreatic ductal adenocarcinoma (PDAC) is a disease where detection preceding clinical symptoms sig...
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer characterized by multiple molecular alter...
Pancreatic ductal adenocarcinoma (PDAC) is an intractable cancer and a leading cause of cancer death...
Purpose: Each year in the United States, � 30,000 people die from pancreatic cancer. Fewer than 5 %...